Holen Sie sich die Stockscreener-App
119.86
2.92%
-3.60
Handel nachbörslich:
120.35
0.49
+0.41%
Schlusskurs vom Vortag:
$123.46
Offen:
$123.17
24-Stunden-Volumen:
266.42K
Relative Volume:
0.85
Marktkapitalisierung:
$1.72B
Einnahmen:
$1.30M
Nettoeinkommen (Verlust:
$-41.72M
KGV:
-32.33
EPS:
-3.7071
Netto-Cashflow:
$-22.82M
1W Leistung:
+8.31%
1M Leistung:
-10.81%
6M Leistung:
+76.39%
1J Leistung:
+399.83%
1-Tages-Spanne:
$119.10
$124.93
1-Wochen-Bereich:
$110.05
$133.06
52-Wochen-Spanne:
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
(484) 253-1461
Adresse
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
119.86 | 1.77B | 1.30M | -41.72M | -22.82M | -3.7071 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Mizuho | Outperform |
| 2025-12-05 | Eingeleitet | BTIG Research | Buy |
| 2025-12-04 | Eingeleitet | Craig Hallum | Buy |
| 2025-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-06 | Eingeleitet | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-04-09 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-26 | Eingeleitet | Stifel | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Palvella appoints McDonough as SVP of market access, patient services - MSN
Breakout Move: What makes Palvella Therapeutics Inc stock attractive today2026 Selloffs & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Palvella Appoints McDonough as SVP of Market Access, Patient Services - MyChesCo
Can Palvella Therapeutics Inc lead its sector in growthPortfolio Update Summary & Safe Entry Zone Identification - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance UK
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
HC Wainwright Brokers Decrease Earnings Estimates for PVLA - marketbeat.com
Lifesci Capital Brokers Decrease Earnings Estimates for PVLA - marketbeat.com
What is HC Wainwright's Estimate for PVLA Q1 Earnings? - marketbeat.com
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Palvella’s Phase III Success And Fast Track Status Test Current Valuation - Yahoo Finance
Mizuho reiterates Palvella Therapeutics stock rating on pipeline By Investing.com - Investing.com Canada
Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating - marketscreener.com
US Stocks Recap: What makes Palvella Therapeutics Inc stock attractive todayEarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus - Sahm
Chardan raises Palvella stock price target to $240 on pipeline progress - Investing.com Canada
Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $240.00 - marketbeat.com
Palvella Highlights 2025 Results and SELVA Phase 3 Progress - TipRanks
Oppenheimer raises Palvella Therapeutics price target on valuation By Investing.com - Investing.com India
Stifel reiterates Buy rating on Palvella stock, $250 target By Investing.com - Investing.com Canada
Oppenheimer raises Palvella Therapeutics price target on valuation - Investing.com
Palvella Therapeutics Announces Positive Phase 3 Results for QTORIN Rapamycin, Prepares NDA Submission and U.S. Launch for Rare Skin Disease Therapies - Minichart
Palvella Therapeutics, Inc. (PVLA) Reports FY2025 Earnings - AlphaStreet
Palvella Therapeutics Q4 2025 Earnings Call Transcript - marketbeat.com
Palvella Therapeutics (NASDAQ:PVLA) Trading 14.4% HigherShould You Buy? - marketbeat.com
PVLA: Positive phase III data, pipeline expansion, and $230M financing position for 2026 NDA submission - TradingView
PALVELLA THERAPEUTICS ($PVLA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
PVLA: Positive phase III data, pipeline growth, and $230M financing position for 2027 FDA approval - TradingView
Palvella Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palvella Therapeutics QTORIN Rapamycin: Novel Treatment Advancements for Rare Skin Diseases and Vascular Malformations - Minichart
Palvella Therapeutics Q4 Earnings Call Highlights - marketbeat.com
Earnings call transcript: Palvella Therapeutics’ Q4 2025 results showcase strong clinical progress By Investing.com - Investing.com South Africa
Earnings call transcript: Palvella Therapeutics’ Q4 2025 results showcase strong clinical progress - Investing.com
European Patent Office grants Palvella patent for QTORIN rapamycin - MSN
Palvella Therapeutics (NASDAQ:PVLA) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - marketbeat.com
OS Therapies Incorporated (OSTX) Reports FY2025 Earnings - AlphaStreet
Palvella 10-K: $0 Revenue, Net Loss $41.7M — Operating Loss $38.6M - TradingView
Palvella Therapeutics (NASDAQ: PVLA) leans on QTORIN data in rare skin diseases - stocktitan.net
Palvella (NASDAQ: PVLA) wins Phase 3 QTORIN data and $230M raise - stocktitan.net
Palvella Therapeutics reports full year 2025 financial results and provides corporate update - marketscreener.com
Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update - TradingView
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
Palvella Therapeutics: Q4 Earnings Snapshot - Barchart.com
Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss - MarketScreener
Palvella announces publication on lymphatic malformation subtypes By Investing.com - za.investing.com
How does Palvella Therapeutics Inc compare to its peersMarket Growth Report & Verified Entry Point Signals - baoquankhu1.vn
Palvella Therapeutics Highlights Continued Progress across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting - marketscreener.com
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations - Bitget
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Palvella Therapeutics Inc-Aktie (PVLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer |
Mar 18 '26 |
Option Exercise |
8.11 |
4,302 |
34,883 |
4,302 |
| Goin Kathleen | Chief Operating Officer |
Mar 18 '26 |
Sale |
117.99 |
4,302 |
507,611 |
0 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):